Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus CHLOROTHIAZIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus CHLOROTHIAZIDE SODIUM.
ANHYDRON vs CHLOROTHIAZIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
500 mg to 1 g orally or intravenously once or twice daily.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic